Seattle Cancer Care Alliance

Pharmacokinetics Laboratory Director / Clinical Consultant: Rosa Yeh, PharmD Medical Director, SCCA Laboratories: Brent Wood, MD PhD

188 East Blaine Street, PO Box 19023, Suite 250, Seattle, WA 98102-3983 Phone: 206-606-7389 Fax: 206-606-7397 CAP: 2463301 CLIA: 50D2169048

Pharmacokinetics Report for Analysis -- Busulfan

Dose Number: 1	Oral Dose Date/Time:	
Number of Samples: 6	IV Dose Date/Time: 9/12/19 6:00	
Ordering Doctor:	Dose Given (mg): 42.00 Q6	
Referring Doctor:	Project Number:	
<u>Description</u>	Result	<u>Units</u>
Area Under the Curve(AUC)	783 for Dose #1	uMol x Min
AUC Target	900 to 1100 per regimen dose	uMol x Min
AUC Estimated Average Exposure	992	uMol x Min
Clearance Rate	4.16	ml/min/kg
Recommended Dosing Type	Q6	
Recommended Dose	60.00	mg
Dose Change	42.9	%
Dose recommended starts at dose #	7	
Dose recommended ends at dose #	16	
Results Reviewed and Approved By	PharmD, BCOP	
Analytical Method	GC-MSD	

Comments:

Note: This test was performed using either gas chromatography with mass selective detection (GC-MSD) or liquid chromatography with mass selective detection (LC-MSD/MSD). This test was developed and its performance characteristics determined by the SCCA Pharmacokinetics Laboratory. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform high complexity clinical laboratory testing.

DISCLAIMER: The SCCA Pharmacokinetics Laboratory dose recommendations are based on patient-specific measured concentrations. It is the sole responsibility of the prescribing provider to determine therapeutic target exposure and initial and final dosing for each patient. The SCCA will not be liable for any damages resulting from injury to the patient due to clinical management by the provider.

END OF REPORT

Referring Diagnosis: AML Location: Referred In SCCA Clinical Lab		Seattle Cancer Care Alliance Fred Hurth - Seattle Children's - UM Medicine
Pharmacokine	tics	